{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:57:02Z","timestamp":1770299822131,"version":"3.49.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,8]]},"DOI":"10.7759\/cureus.22027","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T17:07:16Z","timestamp":1644340036000},"source":"Crossref","is-referenced-by-count":20,"title":["Systemic Lupus Erythematosus and Cardiovascular Disease"],"prefix":"10.7759","author":[{"given":"Surajkumar B","family":"Jha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana P","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela Vanessa","family":"Flores Monar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamza","family":"Islam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sri Madhurima","family":"Puttagunta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabia","family":"Islam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumana","family":"Kundu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Sange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2013.856005","article-title":"Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus","volume":"47","author":"Gustafsson JT","year":"2014","unstructured":"Gustafsson JT, Svenungsson E. Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus. Autoimmunity. 2014, 47:67-76. 10.3109\/08916934.2013.856005","journal-title":"Autoimmunity"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.150","article-title":"The history of lupus throughout the ages [Epub ahead of print]","author":"Felten R","year":"2020","unstructured":"Felten R, Lipsker D, Sibilia J, Chasset F, Arnaud L. The history of lupus throughout the ages [Epub ahead of print]. J Am Acad Dermatol. 2020, 10.1016\/j.jaad.2020.04.150","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206334","article-title":"The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012","volume":"75","author":"Rees F","year":"2016","unstructured":"Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann Rheum Dis. 2016, 75:136-41. 10.1136\/annrheumdis-2014-206334","journal-title":"Ann Rheum Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/berh.2002.0259","article-title":"Epidemiology of systemic lupus erythematosus","volume":"16","author":"Petri M","year":"2002","unstructured":"Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2002, 16:847-58. 10.1053\/berh.2002.0259","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380415","article-title":"The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth","volume":"38","author":"Johnson AE","year":"1995","unstructured":"Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum. 1995, 38:551-8. 10.1002\/art.1780380415","journal-title":"Arthritis Rheum"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1191\/0961203306lu2305xx","article-title":"Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden","volume":"15","author":"Danchenko N","year":"2006","unstructured":"Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006, 15:308-18. 10.1191\/0961203306lu2305xx","journal-title":"Lupus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/096120339500400303","article-title":"Frequency of lupus in people of African origin","volume":"4","author":"Symmons DP","year":"1995","unstructured":"Symmons DP. Frequency of lupus in people of African origin. Lupus. 1995, 4:176-8. 10.1177\/096120339500400303","journal-title":"Lupus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.10.007","article-title":"Understanding the epidemiology and progression of systemic lupus erythematosus","volume":"39","author":"Pons-Estel GJ","year":"2010","unstructured":"Pons-Estel GJ, Alarc\u00f3n GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010, 39:257-68. 10.1016\/j.semarthrit.2008.10.007","journal-title":"Semin Arthritis Rheum"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2017.09.005","article-title":"Understanding the role of environmental factors in the development of systemic lupus erythematosus","volume":"31","author":"Parks CG","year":"2017","unstructured":"Parks CG, de Souza Espindola Santos A, Barbhaiya M, Costenbader KH. Understanding the role of environmental factors in the development of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017, 31:306-20. 10.1016\/j.berh.2017.09.005","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.11.001","article-title":"Systemic lupus erythematosus: diagnosis and clinical management","volume":"96","author":"Fava A","year":"2019","unstructured":"Fava A, Petri M. Systemic lupus erythematosus: diagnosis and clinical management. J Autoimmun. 2019, 96:1-13. 10.1016\/j.jaut.2018.11.001","journal-title":"J Autoimmun"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2017.04.005","article-title":"Lessons learned from twins in autoimmune and chronic inflammatory diseases","volume":"83","author":"Generali E","year":"2017","unstructured":"Generali E, Ceribelli A, Stazi MA, Selmi C. Lessons learned from twins in autoimmune and chronic inflammatory diseases. J Autoimmun. 2017, 83:51-61. 10.1016\/j.jaut.2017.04.005","journal-title":"J Autoimmun"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.08.004","article-title":"Immunogenetics of systemic lupus erythematosus: a comprehensive review","volume":"64","author":"Ghodke-Puranik Y","year":"2015","unstructured":"Ghodke-Puranik Y, Niewold TB. Immunogenetics of systemic lupus erythematosus: a comprehensive review. J Autoimmun. 2015, 64:125-36. 10.1016\/j.jaut.2015.08.004","journal-title":"J Autoimmun"},{"key":"ref13","article-title":"Systemic Lupus Erythematosus","author":"Justiz Vaillant AA","year":"2021","unstructured":"Justiz Vaillant AA, Goyal A, Bansal P, Varacallo M. Systemic Lupus Erythematosus. StatPearls, Treasure Island, FL; 2021."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-089086","article-title":"Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis","volume":"110","author":"Denny MF","year":"2007","unstructured":"Denny MF, Thacker S, Mehta H, et al.. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood. 2007, 110:2907-15. 10.1182\/blood-2007-05-089086","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3198","article-title":"Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity","volume":"103","author":"Rajagopalan S","year":"2004","unstructured":"Rajagopalan S, Somers EC, Brook RD, et al.. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood. 2004, 103:3677-83. 10.1182\/blood-2003-09-3198","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/art.23035","article-title":"Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus","volume":"56","author":"Lee PY","year":"2007","unstructured":"Lee PY, Li Y, Richards HB, et al.. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum. 2007, 56:3759-69. 10.1002\/art.23035","journal-title":"Arthritis Rheum"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/ar2283","article-title":"Reduced number and impaired function of circulating progenitor cells in patients with systemic lupus erythematosus","volume":"9","author":"Moonen JR","year":"2007","unstructured":"Moonen JR, de Leeuw K, van Seijen XJ, Kallenberg CG, van Luyn MJ, Bijl M, Harmsen MC. Reduced number and impaired function of circulating progenitor cells in patients with systemic lupus erythematosus. Arthritis Res Ther. 2007, 9:R84. 10.1186\/ar2283","journal-title":"Arthritis Res Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.065631","article-title":"Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus","volume":"66","author":"Westerweel PE","year":"2007","unstructured":"Westerweel PE, Luijten RK, Hoefer IE, Koomans HA, Derksen RH, Verhaar MC. Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus. Ann Rheum Dis. 2007, 66:865-70. 10.1136\/ard.2006.065631","journal-title":"Ann Rheum Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23495","article-title":"Endothelial dysfunction in early systemic lupus erythematosus patients and controls without previous cardiovascular events","volume":"70","author":"Taraborelli M","year":"2018","unstructured":"Taraborelli M, Sciatti E, Bonadei I, et al.. Endothelial dysfunction in early systemic lupus erythematosus patients and controls without previous cardiovascular events. Arthritis Care Res (Hoboken). 2018, 70:1277-83. 10.1002\/acr.23495","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref20","article-title":"Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus","volume":"35","author":"Rho YH","year":"2008","unstructured":"Rho YH, Chung CP, Oeser A, et al.. Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J Rheumatol. 2008, 35:1789-94.","journal-title":"J Rheumatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.116.308126","article-title":"Activated platelets induce endothelial cell activation via an interleukin-1\u03b2 pathway in systemic lupus erythematosus","volume":"37","author":"Nhek S","year":"2017","unstructured":"Nhek S, Clancy R, Lee KA, et al.. Activated platelets induce endothelial cell activation via an interleukin-1\u03b2 pathway in systemic lupus erythematosus. Arterioscler Thromb Vasc Biol. 2017, 37:707-16. 10.1161\/ATVBAHA.116.308126","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037000","article-title":"Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients","volume":"7","author":"Somers EC","year":"2012","unstructured":"Somers EC, Zhao W, Lewis EE, et al.. Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS One. 2012, 7:e37000. 10.1371\/journal.pone.0037000","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000508","article-title":"Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus","volume":"3","author":"Tyd\u00e9n H","year":"2017","unstructured":"Tyd\u00e9n H, Lood C, Gullstrand B, et al.. Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus. RMD Open. 2017, 3:e000508. 10.1136\/rmdopen-2017-000508","journal-title":"RMD Open"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4428","article-title":"IRF3 and type I interferons fuel a fatal response to myocardial infarction","volume":"23","author":"King KR","year":"2017","unstructured":"King KR, Aguirre AD, Ye YX, et al.. IRF3 and type I interferons fuel a fatal response to myocardial infarction. Nat Med. 2017, 23:1481-7. 10.1038\/nm.4428","journal-title":"Nat Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283546703","article-title":"Lupus neutrophils: 'NET' gain in understanding lupus pathogenesis","volume":"24","author":"Knight JS","year":"2012","unstructured":"Knight JS, Kaplan MJ. Lupus neutrophils: 'NET' gain in understanding lupus pathogenesis. Curr Opin Rheumatol. 2012, 24:441-50. 10.1097\/BOR.0b013e3283546703","journal-title":"Curr Opin Rheumatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99276","article-title":"Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus","volume":"3","author":"Carlucci PM","year":"2018","unstructured":"Carlucci PM, Purmalek MM, Dey AK, et al.. Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus. JCI Insight. 2018, 3:276. 10.1172\/jci.insight.99276","journal-title":"JCI Insight"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203759","article-title":"Dysregulated CD4+ T cells from SLE-susceptible mice are sufficient to accelerate atherosclerosis in LDLr-\/- mice","volume":"74","author":"Wilhelm AJ","year":"2015","unstructured":"Wilhelm AJ, Rhoads JP, Wade NS, Major AS. Dysregulated CD4+ T cells from SLE-susceptible mice are sufficient to accelerate atherosclerosis in LDLr-\/- mice. Ann Rheum Dis. 2015, 74:778-85. 10.1136\/annrheumdis-2013-203759","journal-title":"Ann Rheum Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.07.001","article-title":"CD4+CXCR3+ T cells and plasmacytoid dendritic cells drive accelerated atherosclerosis associated with systemic lupus erythematosus","volume":"63","author":"Clement M","year":"2015","unstructured":"Clement M, Charles N, Escoubet B, et al.. CD4+CXCR3+ T cells and plasmacytoid dendritic cells drive accelerated atherosclerosis associated with systemic lupus erythematosus. J Autoimmun. 2015, 63:59-67. 10.1016\/j.jaut.2015.07.001","journal-title":"J Autoimmun"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2017.09.001","article-title":"Disease trends over time and CD4+CCR5+ T-cells expansion predict carotid atherosclerosis development in patients with systemic lupus erythematosus","volume":"28","author":"Baragetti A","year":"2018","unstructured":"Baragetti A, Ramirez GA, Magnoni M, et al.. Disease trends over time and CD4+CCR5+ T-cells expansion predict carotid atherosclerosis development in patients with systemic lupus erythematosus. Nutr Metab Cardiovasc Dis. 2018, 28:53-63. 10.1016\/j.numecd.2017.09.001","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aah4081","article-title":"Cross-talk between iNKT cells and monocytes triggers an atheroprotective immune response in SLE patients with asymptomatic plaque","volume":"1","author":"Smith E","year":"2016","unstructured":"Smith E, Croca S, Waddington KE, et al.. Cross-talk between iNKT cells and monocytes triggers an atheroprotective immune response in SLE patients with asymptomatic plaque. Sci Immunol. 2016, 1:4081. 10.1126\/sciimmunol.aah4081","journal-title":"Sci Immunol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.05.002","article-title":"B-cell activating factor and related genetic variants in lupus related atherosclerosis","volume":"92","author":"Theodorou E","year":"2018","unstructured":"Theodorou E, Nezos A, Antypa E, et al.. B-cell activating factor and related genetic variants in lupus related atherosclerosis. J Autoimmun. 2018, 92:87-92. 10.1016\/j.jaut.2018.05.002","journal-title":"J Autoimmun"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key233","article-title":"Progression of subclinical atherosclerosis in systemic lupus erythematosus versus rheumatoid arthritis: the impact of low disease activity","volume":"57","author":"Kravvariti E","year":"2018","unstructured":"Kravvariti E, Konstantonis G, Sfikakis PP, Tektonidou MG. Progression of subclinical atherosclerosis in systemic lupus erythematosus versus rheumatoid arthritis: the impact of low disease activity. Rheumatology (Oxford). 2018, 57:2158-66. 10.1093\/rheumatology\/key233","journal-title":"Rheumatology (Oxford)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204600","article-title":"Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus","volume":"74","author":"Perez-Sanchez C","year":"2015","unstructured":"Perez-Sanchez C, Barbarroja N, Messineo S, et al.. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. Ann Rheum Dis. 2015, 74:1441-9. 10.1136\/annrheumdis-2013-204600","journal-title":"Ann Rheum Dis"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000429","article-title":"Anti-Ro and concomitant anti-La autoantibodies strongly associated with anti-oxLDL or anti-phospholipid antibody in systemic lupus erythematosus","volume":"22","author":"Kurien BT","year":"2016","unstructured":"Kurien BT, Fesmire J, Anderson CJ, Scofield RH. Anti-Ro and concomitant anti-La autoantibodies strongly associated with anti-oxLDL or anti-phospholipid antibody in systemic lupus erythematosus. J Clin Rheumatol. 2016, 22:418-25. 10.1097\/RHU.0000000000000429","journal-title":"J Clin Rheumatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1422.009","article-title":"Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus","volume":"1108","author":"Kiss E","year":"2007","unstructured":"Kiss E, Seres I, Tarr T, Kocsis Z, Szegedi G, Paragh G. Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. Ann N Y Acad Sci. 2007, 1108:83-91. 10.1196\/annals.1422.009","journal-title":"Ann N Y Acad Sci"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1160\/TH17-03-0221","article-title":"Serum levels of anti-PON1 and anti-HDL antibodies as potential biomarkers of premature atherosclerosis in systemic lupus erythematosus","volume":"117","author":"L\u00f3pez P","year":"2017","unstructured":"L\u00f3pez P, Rodr\u00edguez-Carrio J, Mart\u00ednez-Zapico A, et al.. Serum levels of anti-PON1 and anti-HDL antibodies as potential biomarkers of premature atherosclerosis in systemic lupus erythematosus. Thromb Haemost. 2017, 117:2194-206. 10.1160\/TH17-03-0221","journal-title":"Thromb Haemost"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1422.016","article-title":"Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus","volume":"1108","author":"Batuca JR","year":"2007","unstructured":"Batuca JR, Ames PR, Isenberg DA, Alves JD. Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus. Ann N Y Acad Sci. 2007, 1108:137-46. 10.1196\/annals.1422.016","journal-title":"Ann N Y Acad Sci"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2016.56","article-title":"ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease","volume":"96","author":"Chistiakov DA","year":"2016","unstructured":"Chistiakov DA, Orekhov AN, Bobryshev YV. ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease. Lab Invest. 2016, 96:708-18. 10.1038\/labinvest.2016.56","journal-title":"Lab Invest"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.04748.x","article-title":"Natural antibodies against phosphorylcholine in cardiovascular disease","volume":"1173","author":"de Faire U","year":"2009","unstructured":"de Faire U, Frosteg\u00e5rd J. Natural antibodies against phosphorylcholine in cardiovascular disease. Ann N Y Acad Sci. 2009, 1173:292-300. 10.1111\/j.1749-6632.2009.04748.x","journal-title":"Ann N Y Acad Sci"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.11.054","article-title":"Phosphorylcholine-targeting immunization reduces atherosclerosis","volume":"50","author":"Caligiuri G","year":"2007","unstructured":"Caligiuri G, Khallou-Laschet J, Vandaele M, et al.. Phosphorylcholine-targeting immunization reduces atherosclerosis. J Am Coll Cardiol. 2007, 50:540-6. 10.1016\/j.jacc.2006.11.054","journal-title":"J Am Coll Cardiol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12651","article-title":"Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus","volume":"181","author":"Svenungsson E","year":"2015","unstructured":"Svenungsson E, Engelbertsen D, Wigren M, et al.. Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus. Clin Exp Immunol. 2015, 181:417-26. 10.1111\/cei.12651","journal-title":"Clin Exp Immunol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2017.11.010","article-title":"IgM antibodies against phosphorylcholine promote polarization of T regulatory cells from patients with atherosclerotic plaques, systemic lupus erythematosus and healthy donors","volume":"268","author":"Sun J","year":"2018","unstructured":"Sun J, Lundstr\u00f6m SL, Zhang B, et al.. IgM antibodies against phosphorylcholine promote polarization of T regulatory cells from patients with atherosclerotic plaques, systemic lupus erythematosus and healthy donors. Atherosclerosis. 2018, 268:36-48. 10.1016\/j.atherosclerosis.2017.11.010","journal-title":"Atherosclerosis"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2016.04.007","article-title":"IgM antibodies against malondialdehyde and phosphorylcholine are together strong protection markers for atherosclerosis in systemic lupus erythematosus: Regulation and underlying mechanisms","volume":"166","author":"Rahman M","year":"2016","unstructured":"Rahman M, Sing S, Golabkesh Z, et al.. IgM antibodies against malondialdehyde and phosphorylcholine are together strong protection markers for atherosclerosis in systemic lupus erythematosus: Regulation and underlying mechanisms. Clin Immunol. 2016, 166:27-37. 10.1016\/j.clim.2016.04.007","journal-title":"Clin Immunol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-016-8892-9","article-title":"Dyslipidemia in systemic lupus erythematosus","volume":"65","author":"Szab\u00f3 MZ","year":"2017","unstructured":"Szab\u00f3 MZ, Szodoray P, Kiss E. Dyslipidemia in systemic lupus erythematosus. Immunol Res. 2017, 65:543-50. 10.1007\/s12026-016-8892-9","journal-title":"Immunol Res"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1002\/art.38703","article-title":"Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus","volume":"66","author":"Smith CK","year":"2014","unstructured":"Smith CK, Vivekanandan-Giri A, Tang C, et al.. Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus. Arthritis Rheumatol. 2014, 66:2532-44. 10.1002\/art.38703","journal-title":"Arthritis Rheumatol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202914","article-title":"Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus","volume":"73","author":"Ronda N","year":"2014","unstructured":"Ronda N, Favari E, Borghi MO, et al.. Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis. 2014, 73:609-15. 10.1136\/annrheumdis-2012-202914","journal-title":"Ann Rheum Dis"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1002\/art.21976","article-title":"Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"54","author":"McMahon M","year":"2006","unstructured":"McMahon M, Grossman J, FitzGerald J, et al.. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006, 54:2541-9. 10.1002\/art.21976","journal-title":"Arthritis Rheum"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2784","article-title":"High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3","volume":"15","author":"De Nardo D","year":"2014","unstructured":"De Nardo D, Labzin LI, Kono H, et al.. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol. 2014, 15:152-60. 10.1038\/ni.2784","journal-title":"Nat Immunol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209683","article-title":"Lupus high-density lipoprotein induces proinflammatory responses in macrophages by binding lectin-like oxidised low-density lipoprotein receptor 1 and failing to promote activating transcription factor 3 activity","volume":"76","author":"Smith CK","year":"2017","unstructured":"Smith CK, Seto NL, Vivekanandan-Giri A, et al.. Lupus high-density lipoprotein induces proinflammatory responses in macrophages by binding lectin-like oxidised low-density lipoprotein receptor 1 and failing to promote activating transcription factor 3 activity. Ann Rheum Dis. 2017, 76:602-11. 10.1136\/annrheumdis-2016-209683","journal-title":"Ann Rheum Dis"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23237","article-title":"Increased insulin resistance and glucagon levels in mild\/inactive systemic lupus erythematosus patients despite normal glucose tolerance","volume":"70","author":"Miyake CN","year":"2018","unstructured":"Miyake CN, Gualano B, Dantas WS, et al.. Increased insulin resistance and glucagon levels in mild\/inactive systemic lupus erythematosus patients despite normal glucose tolerance. Arthritis Care Res (Hoboken). 2018, 70:114-24. 10.1002\/acr.23237","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S321311","article-title":"Effect of leptin on chronic inflammatory disorders: insights to therapeutic target to prevent further cardiovascular complication","volume":"14","author":"Dessie G","year":"2021","unstructured":"Dessie G, Ayelign B, Akalu Y, Shibabaw T, Molla MD. Effect of leptin on chronic inflammatory disorders: insights to therapeutic target to prevent further cardiovascular complication. Diabetes Metab Syndr Obes. 2021, 14:3307-22. 10.2147\/DMSO.S321311","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12757","article-title":"Smoking and obesity in systemic lupus erythematosus: a cross-sectional study","volume":"47","author":"Versini M","year":"2017","unstructured":"Versini M, Tiosano S, Comaneshter D, Shoenfeld Y, Cohen AD, Amital H. Smoking and obesity in systemic lupus erythematosus: a cross-sectional study. Eur J Clin Invest. 2017, 47:422-7. 10.1111\/eci.12757","journal-title":"Eur J Clin Invest"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejr.2017.06.005","article-title":"Serum leptin in systemic lupus erythematosus patients: its correlation with disease activity and some disease parameters","volume":"40","author":"Mohammed SF","year":"2018","unstructured":"Mohammed SF, Abdalla MA, Ismaeil WM, Sheta MM. Serum leptin in systemic lupus erythematosus patients: its correlation with disease activity and some disease parameters. Egypt Rheumatol. 2018, 40:23-7. 10.1016\/j.ejr.2017.06.005","journal-title":"Egypt Rheumatol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1002\/art.23352","article-title":"Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus?","volume":"59","author":"Karp I","year":"2008","unstructured":"Karp I, Abrahamowicz M, Fortin PR, Pilote L, Neville C, Pineau CA, Esdaile JM. Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus?. Arthritis Rheum. 2008, 59:169-75. 10.1002\/art.23352","journal-title":"Arthritis Rheum"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90578-y","article-title":"Risk factors for coronary artery disease in patients with systemic lupus erythematosus","volume":"93","author":"Petri M","year":"1992","unstructured":"Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992, 93:513-9. 10.1016\/0002-9343(92)90578-y","journal-title":"Am J Med"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1186\/ar3473","article-title":"Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study","volume":"13","author":"Nikpour M","year":"2011","unstructured":"Nikpour M, Urowitz MB, Ibanez D, Harvey PJ, Gladman DD. Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. Arthritis Res Ther. 2011, 13:R156. 10.1186\/ar3473","journal-title":"Arthritis Res Ther"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20122","article-title":"Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus","volume":"62","author":"Urowitz MB","year":"2010","unstructured":"Urowitz MB, Gladman D, Iba\u00f1ez D, et al.. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010, 62:881-7. 10.1002\/acr.20122","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1177\/0961203307081113","article-title":"Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort","volume":"16","author":"Urowitz MB","year":"2007","unstructured":"Urowitz MB, Gladman D, Iba\u00f1ez D, et al.. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus. 2007, 16:731-5. 10.1177\/0961203307081113","journal-title":"Lupus"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep102","article-title":"Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort","volume":"48","author":"Pons-Estel GJ","year":"2009","unstructured":"Pons-Estel GJ, Gonz\u00e1lez LA, Zhang J, Burgos PI, Reveille JD, Vil\u00e1 LM, Alarc\u00f3n GS. Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology (Oxford). 2009, 48:817-22. 10.1093\/rheumatology\/kep102","journal-title":"Rheumatology (Oxford)"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309105877","article-title":"Peripheral vascular damage in systemic lupus erythematosus: data from LUMINA, a large multi-ethnic U.S. cohort (LXIX)","volume":"18","author":"Burgos PI","year":"2009","unstructured":"Burgos PI, Vil\u00e1 LM, Reveille JD, Alarc\u00f3n GS. Peripheral vascular damage in systemic lupus erythematosus: data from LUMINA, a large multi-ethnic U.S. cohort (LXIX). Lupus. 2009, 18:1303-8. 10.1177\/0961203309105877","journal-title":"Lupus"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090306","article-title":"Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study","volume":"37","author":"Haque S","year":"2010","unstructured":"Haque S, Gordon C, Isenberg D, et al.. Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. J Rheumatol. 2010, 37:322-9. 10.3899\/jrheum.090306","journal-title":"J Rheumatol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23018","article-title":"Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: a general population\u2010based study","volume":"69","author":"Avi\u00f1a-Zubieta JA","year":"2017","unstructured":"Avi\u00f1a-Zubieta JA, To F, Vostretsova K, De Vera M, Sayre EC, Esdaile JM. Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: a general population\u2010based study. Arthritis Care Res (Hoboken). 2017, 69:849-56. 10.1002\/acr.23018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1002\/art.21955","article-title":"Mortality in systemic lupus erythematosus","volume":"54","author":"Bernatsky S","year":"2006","unstructured":"Bernatsky S, Boivin JF, Joseph L, et al.. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006, 54:2550-7. 10.1002\/art.21955","journal-title":"Arthritis Rheum"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009122","article-title":"Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study","volume":"145","author":"Manzi S","year":"1997","unstructured":"Manzi S, Meilahn EN, Rairie JE, et al.. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997, 145:408-15. 10.1093\/oxfordjournals.aje.a009122","journal-title":"Am J Epidemiol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.10.002","article-title":"Subclinical atherosclerosis in patients with systemic lupus erythematosus: a systemic review and meta-analysis","volume":"15","author":"Wu GC","year":"2016","unstructured":"Wu GC, Liu HR, Leng RX, Li XP, Li XM, Pan HF, Ye DQ. Subclinical atherosclerosis in patients with systemic lupus erythematosus: a systemic review and meta-analysis. Autoimmun Rev. 2016, 15:22-37. 10.1016\/j.autrev.2015.10.002","journal-title":"Autoimmun Rev"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1177\/0003319715613917","article-title":"Early vascular aging in normotensive patients with systemic lupus erythematosus: comparison with young patients having hypertension","volume":"67","author":"Morreale M","year":"2016","unstructured":"Morreale M, Mul\u00e8 G, Ferrante A, D'ignoto F, Cottone S. Early vascular aging in normotensive patients with systemic lupus erythematosus: comparison with young patients having hypertension. Angiology. 2016, 67:676-82. 10.1177\/0003319715613917","journal-title":"Angiology"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/765253","article-title":"Proximal aortic stiffness is increased in systemic lupus erythematosus activity in children and adolescents","volume":"2013","author":"El Gamal YM","year":"2013","unstructured":"El Gamal YM, Elmasry OA, El Hadidi IS, Soliman OK. Proximal aortic stiffness is increased in systemic lupus erythematosus activity in children and adolescents. ISRN Pediatr. 2013, 2013:765253. 10.1155\/2013\/765253","journal-title":"ISRN Pediatr"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2012.12.002","article-title":"The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review","volume":"43","author":"Schoenfeld SR","year":"2013","unstructured":"Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013, 43:77-95. 10.1016\/j.semarthrit.2012.12.002","journal-title":"Semin Arthritis Rheum"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200110)44:10<2331::aid-art395>3.0.co;2-i","article-title":"Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus","volume":"44","author":"Esdaile JM","year":"2001","unstructured":"Esdaile JM, Abrahamowicz M, Grodzicky T, et al.. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001, 44:2331-7. 10.1002\/1529-0131(200110)44:10&lt;2331::aid-art395&gt;3.0.co;2-i","journal-title":"Arthritis Rheum"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1177\/0961203317731533","article-title":"Cardiovascular magnetic resonance detects silent heart disease missed by echocardiography in systemic lupus erythematosus","volume":"27","author":"Mavrogeni S","year":"2018","unstructured":"Mavrogeni S, Koutsogeorgopoulou L, Markousis-Mavrogenis G, et al.. Cardiovascular magnetic resonance detects silent heart disease missed by echocardiography in systemic lupus erythematosus. Lupus. 2018, 27:564-71. 10.1177\/0961203317731533","journal-title":"Lupus"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1177\/0961203318758504","article-title":"Increased visceral adipose tissue and altered adiposity distribution in premenopausal lupus patients: correlation with cardiovascular risk factors","volume":"27","author":"Seguro LP","year":"2018","unstructured":"Seguro LP, Paupitz JA, Caparbo VF, Bonfa E, Pereira RM. Increased visceral adipose tissue and altered adiposity distribution in premenopausal lupus patients: correlation with cardiovascular risk factors. Lupus. 2018, 27:1001-6. 10.1177\/0961203318758504","journal-title":"Lupus"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2017.04.021","article-title":"Association of aortic perivascular adipose tissue density with aortic calcification in women with systemic lupus erythematosus","volume":"262","author":"Shields KJ","year":"2017","unstructured":"Shields KJ, El Khoudary SR, Ahearn JM, Manzi S. Association of aortic perivascular adipose tissue density with aortic calcification in women with systemic lupus erythematosus. Atherosclerosis. 2017, 262:55-61. 10.1016\/j.atherosclerosis.2017.04.021","journal-title":"Atherosclerosis"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.83.3.902","article-title":"Diagnostic efficiency of troponin T measurements in acute myocardial infarction","volume":"83","author":"Katus HA","year":"1991","unstructured":"Katus HA, Remppis A, Neumann FJ, et al.. Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation. 1991, 83:902-12. 10.1161\/01.cir.83.3.902","journal-title":"Circulation"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.005264","article-title":"Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study","volume":"123","author":"Saunders JT","year":"2011","unstructured":"Saunders JT, Nambi V, de Lemos JA, et al.. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011, 123:1367-76. 10.1161\/CIRCULATIONAHA.110.005264","journal-title":"Circulation"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1352-7","article-title":"High-sensitivity cardiac troponin T is a biomarker for atherosclerosis in systemic lupus erythematous patients: a cross-sectional controlled study","volume":"19","author":"Divard G","year":"2017","unstructured":"Divard G, Abbas R, Chenevier-Gobeaux C, et al.. High-sensitivity cardiac troponin T is a biomarker for atherosclerosis in systemic lupus erythematous patients: a cross-sectional controlled study. Arthritis Res Ther. 2017, 19:132. 10.1186\/s13075-017-1352-7","journal-title":"Arthritis Res Ther"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8175.2012.01797.x","article-title":"Association between serum total antioxidant status and coronary microvascular functions in patients with SLE","volume":"29","author":"Y\u0131lmaz S","year":"2012","unstructured":"Y\u0131lmaz S, Caliskan M, Kulaks\u0131zoglu S, et al.. Association between serum total antioxidant status and coronary microvascular functions in patients with SLE. Echocardiography. 2012, 29:1218-23. 10.1111\/j.1540-8175.2012.01797.x","journal-title":"Echocardiography"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000194","article-title":"How HDL protects LDL against atherogenic modification: paraoxonase 1 and other dramatis personae","volume":"26","author":"Soran H","year":"2015","unstructured":"Soran H, Schofield JD, Liu Y, Durrington PN. How HDL protects LDL against atherogenic modification: paraoxonase 1 and other dramatis personae. Curr Opin Lipidol. 2015, 26:247-56. 10.1097\/MOL.0000000000000194","journal-title":"Curr Opin Lipidol"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1002\/art.10542","article-title":"Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome","volume":"46","author":"Delgado Alves J","year":"2002","unstructured":"Delgado Alves J, Ames PR, Donohue S, Stanyer L, Nourooz-Zadeh J, Ravirajan C, Isenberg DA. Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum. 2002, 46:2686-94. 10.1002\/art.10542","journal-title":"Arthritis Rheum"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.01.022","article-title":"Cardiovascular disease in systemic lupus erythematosus is associated with increased levels of biomarkers reflecting receptor-activated apoptosis","volume":"270","author":"Wigren M","year":"2018","unstructured":"Wigren M, Svenungsson E, Mattisson IY, et al.. Cardiovascular disease in systemic lupus erythematosus is associated with increased levels of biomarkers reflecting receptor-activated apoptosis. Atherosclerosis. 2018, 270:1-7. 10.1016\/j.atherosclerosis.2018.01.022","journal-title":"Atherosclerosis"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.2174\/1570161118666191227101636","article-title":"Cardiovascular disease in systemic lupus erythematosus: recent data on epidemiology, risk factors and prevention","volume":"18","author":"Kostopoulou M","year":"2020","unstructured":"Kostopoulou M, Nikolopoulos D, Parodis I, Bertsias G. Cardiovascular disease in systemic lupus erythematosus: recent data on epidemiology, risk factors and prevention. Curr Vasc Pharmacol. 2020, 18:549-65. 10.2174\/1570161118666191227101636","journal-title":"Curr Vasc Pharmacol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR)","volume":"37","author":"Piepoli MF","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, et al.. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention &amp;amp; Rehabilitation (EACPR). Eur Heart J. 2016, 37:2315-81. 10.1093\/eurheartj\/ehw106","journal-title":"Eur Heart J"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216764","article-title":"Impact of the new American College of Cardiology\/American Heart Association definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus","volume":"79","author":"Tselios K","year":"2020","unstructured":"Tselios K, Gladman DD, Su J, Urowitz M. Impact of the new American College of Cardiology\/American Heart Association definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus. Ann Rheum Dis. 2020, 79:612-7. 10.1136\/annrheumdis-2019-216764","journal-title":"Ann Rheum Dis"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton PK","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al.. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018, 71:e127-248. 10.1016\/j.jacc.2017.11.006","journal-title":"J Am Coll Cardiol"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams B","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, et al.. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018, 39:3021-104. 10.1093\/eurheartj\/ehy339","journal-title":"Eur Heart J"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207719","article-title":"Outcomes of percutaneous coronary intervention in patients with rheumatoid arthritis and systemic lupus erythematosus: an 11-year nationwide cohort study","volume":"75","author":"Lai CH","year":"2016","unstructured":"Lai CH, Lai WW, Chiou MJ, Lin WC, Yang YJ, Li CY, Tsai LM. Outcomes of percutaneous coronary intervention in patients with rheumatoid arthritis and systemic lupus erythematosus: an 11-year nationwide cohort study. Ann Rheum Dis. 2016, 75:1350-6. 10.1136\/annrheumdis-2015-207719","journal-title":"Ann Rheum Dis"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza G","year":"2010","unstructured":"Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010, 69:20-8. 10.1136\/ard.2008.101766","journal-title":"Ann Rheum Dis"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.093013","article-title":"Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort","volume":"68","author":"Kaiser R","year":"2009","unstructured":"Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis. 2009, 68:238-41. 10.1136\/ard.2008.093013","journal-title":"Ann Rheum Dis"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1002\/art.27289","article-title":"The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus","volume":"62","author":"Jung H","year":"2010","unstructured":"Jung H, Bobba R, Su J, et al.. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 2010, 62:863-8. 10.1002\/art.27289","journal-title":"Arthritis Rheum"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1177\/0961203306071872","article-title":"Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus","volume":"15","author":"Ruiz-Irastorza G","year":"2006","unstructured":"Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al.. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006, 15:577-83. 10.1177\/0961203306071872","journal-title":"Lupus"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090994","article-title":"Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus","volume":"37","author":"Penn SK","year":"2010","unstructured":"Penn SK, Kao AH, Schott LL, et al.. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol. 2010, 37:1136-42. 10.3899\/jrheum.090994","journal-title":"J Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/85135-systemic-lupus-erythematosus-and-cardiovascular-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:44:29Z","timestamp":1707507869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/85135-systemic-lupus-erythematosus-and-cardiovascular-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,8]]},"references-count":90,"URL":"https:\/\/doi.org\/10.7759\/cureus.22027","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,8]]}}}